Posted by Michael Wonder on 24 Sep 2023
MicuRx receives FDA qualified infectious disease product and fast track designation for contezolid and contezolid acefosamil
22 September 2023 - MicuRx Pharmaceuticals today announced that the US FDA has granted Qualified Infectious Disease Product and the fast track designation under the Generating Antibiotic Incentives Now (GAIN) Act for contezolid tablet and contezolid acefosamil tablet and intravenous as novel new oxazolidinone antibiotics for the treatment of moderate to severe diabetic foot infection without concomitant osteomyelitis.
Oral contezolid and intravenous contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with diabetic foot infection.
